Relay Therapeutics, Inc. (RLAY) Tops Q4 EPS by 14c

Relay Therapeutics, Inc. (NASDAQ: RLAY) reported Q4 EPS of ($0.56), $0.14 better than the analyst estimate of ($0.70). Revenue for the quarter came in at $250 thousand versus the consensus estimate of $233.33 thousand.

For earnings history and earnings-related data on Relay Therapeutics, Inc. (RLAY) click here.

You May Also Be Interested In

• Raymond James Downgrades Phreesia Inc. (PHR) to Market Perform
• Morgan Stanley Upgrades M&T Bank (MTB) to Overweight
• Evercore ISI on Jersey Mike's Subs (JMKE): 'Anticipating a positive outlook'